Imunon, Inc. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
On September 28, 2026, Imunon, Inc. exchanged $1.2M of a $2.72M Secured Promissory Note (originally issued June 2, 2026 to Streeterville Capital, LLC) for 120 shares of newly designated Series B Preferred Stock with a stated value of $12,000/share ($1.44M total). The Series B stock carries 8% annual preferred return (15% upon default), is senior to common stock, requires majority Series B holder consent for future capital actions, and restricts the company from various material transactions without investor approval.
Why this rating
Major debt-to-equity conversion giving investor substantial control rights over a $21.2M company via strict covenants; materially dilutes equity and constrains future financing flexibility.
Tradability signal
NO TRADE
No trade: only ~$68k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it negative)
before filing · preread $1.43 ▲ 3.52% | at our read · unknown $1.38 | +10 min · unknown $1.40 ▲ 1.45% | +30 min pending | +1 hr pending | +4 hrs pending |
The stock had already moved -3.40% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.